Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Journal of Medicinal Chemistry|September 15, 1995
Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activityC F Bigge, T C Malone, P A Boxer, et al.
Advances in Experimental Medicine and Biology|August 30, 2017
Analysis of Neuroprotection by Taurine and Taurine Combinations in Primary Neuronal Cultures and in Neuronal Cell Lines Exposed to Glutamate Excitotoxicity and to Hypoxia/Re-oxygenationHoward Prentice, Chunliu Pan, Payam M Gharibani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancerJ Bellmunt, B J Eigl, E Senkus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancerJ W F Catto, B Tran, M Rouprêt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)M De Santis, P J Wiechno, J Bellmunt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274M D Galsky, J E Gschwend, M I Milowsky, et al.
European Urology|December 24, 2017
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of RegimensJose Luis Perez-Gracia, Yohann Loriot, Jonathan E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyJ N Graff, M Burotto, P C Fong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Pageof 16